The Cancer Review brings you the latest news, analysis and research in the cancer industry. It covers all the major current business issues and events, ranging from R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

• Strategic insight into the future shape of cancer companies and markets

  
  

• The most significant cancer industry news compiled into one monthly update

  
  

• Expert analysis into the implications of the month's important cancer industry events

  
  

• Insight into the future shape of the market for players at all levels

  
  

• All the month's cancer stories in headline and summary form

  
  

Out of the dozens of topics covered in this month's review, the most important include:

* Japan became the first country to approve AstraZeneca's Iressa for the treatment of inoperable or recurrent non-small cell lung cancer. Iressa is the first in a new class of anti-cancer drugs, known as EGF receptor inhibitors.

* Five non-profitable UK biotech companies may be considering a merger, creating a new cancer player capable of competing against the majors. But a more gradual consolidation effort might suit the biotechs better

• Not only keeps you updated about industry events - it also gives you opinion and insight

  
  

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

  
  

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

  
  

The most significant news in breast cancer R&D, compiled into one monthly update.

The most significant news in lung cancer R&D, compiled into one monthly update.

The most significant news in prostate cancer R&D, compiled into one monthly update.

The most significant news in colorectal cancer R&D, compiled into one monthly update.

The most significant news in other cancers, compiled into one monthly update including:

• Lymphoma and leukemia
  
  
  
• Brain cancer
  
  
  
• Ovarian cancer
  
  
  
• Skin cancers
  
  
  

Expert analysis into the implications of the month's important industry events

• Xenova/QLT: tackling multidrug resistance
  
  
  
• Cancer survival: UK at the bottom of the league
  
  
  
• AstraZeneca: fighting cancer in the East
  
  
  
• Roche/Schering-Plough: interferon therapy shows potential
  
  
  
• Schering-Plough: a NICE decision for Caelyx
  
  
  
• Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug
  
  
  
• Pfizer/Pharmacia: boosting the cancer market
  
  
  
• Aspirin: preventing heart attacks, stroke and cancer
  
  
  
• Sanofi-Synthelabo: elated by Eloxatin news
  
  
  
• UK biotechs: biting off more than they can chew
  
  
  

Analyst-written feature articles, featuring the latest insights into the industry

• Pfizer/Pharmacia: laying down a challenge to fellow big pharmas
  
  
  

Insight into the future shape of the market for players at all levels

• Leukemia: incidence to reach 74,460 in 2010
  
  
  
• Colorectal cancer: 90% survival rate in stage I
  
  
  

All the month's breast cancer news stories in headline and summary form

All the month's lung cancer news stories in headline and summary form

All the month's prostate cancer news stories in headline and summary form

All the month's colorectal cancer news stories in headline and summary form

All the month's other cancer news stories in headline and summary form